Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64

Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc.

PTHS

0.00

Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX: PTHS) with a Outperform and lowers the price target from $66 to $64.